LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

B.C. Cho, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Jin Sun Lee, SH Lee, Y.V. Ostapenko, Pongwut Danchaivijitr, B. Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Tao Sun, Melissa Martínez, Joshua Bauml, Martin Shreeve, Seema Sethi, Roland E. Knoblauch, Hidetoshi Hayashi, Shun Lü